Go to Home page Go to Home page
Making an impact
beyond skin-deep
We develop dermato-oncology treatments with the goal of healing and curing disease and conditions beyond skin-deep.
View Research & Innovation
5M
Non-melanoma skin cancer incidence

Skin cancers are the most common groups of cancers diagnosed worldwide.

Highlight Therapeutics' R&D focuses on RNA-based therapy. Our lead candidate, BO-112, triggers a potent immune response, transforming "cold" tumors into "hot" ones, making them visible to the immune system.
BO–112

Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.

BO–112

Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.

Manifesto
Revolutionizing Dermato-oncology

Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.

Discover our purpose
Manifesto
Revolutionizing Dermato-oncology

Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.

Discover our purpose
About us
Meet our team of experts

Meet our team of experts dedicated to pioneering breakthroughs in therapeutics. Their unparalleled expertise & passion drive our mission to transform dermato-oncology.

See our company
About us
Meet our team of experts

Meet our team of experts dedicated to pioneering breakthroughs in therapeutics. Their unparalleled expertise & passion drive our mission to transform dermato-oncology.

See our company
Pipeline
With established clinical results in oncology Highlight is now transforming dermato-oncology
Dermato-oncology
Preclinica
Phase 1
Phase 2
Phase 3
See how Highlight Therapeutics is tackling the global issue of dermato-oncology.
"The combination of BO-112 and anti-PD-1 is a promising advance in cancer immunotherapy. Our results highlight its safety and ability to trigger anti-tumour responses, offering hope for patients with resistance to conventional treatments."
Marisol Quintero
Chief executive Officer
Unlocking the potential of
dermato-oncology treatment
Contact us